AIRLINK 66.80 Increased By ▲ 2.21 (3.42%)
BOP 5.67 Increased By ▲ 0.07 (1.25%)
CNERGY 4.63 Decreased By ▼ -0.09 (-1.91%)
DFML 22.32 Increased By ▲ 1.56 (7.51%)
DGKC 69.76 Decreased By ▼ -1.64 (-2.3%)
FCCL 19.62 Decreased By ▼ -0.33 (-1.65%)
FFBL 30.20 Decreased By ▼ -0.25 (-0.82%)
FFL 9.90 Decreased By ▼ -0.15 (-1.49%)
GGL 10.05 No Change ▼ 0.00 (0%)
HBL 115.70 Increased By ▲ 4.70 (4.23%)
HUBC 130.51 Decreased By ▼ -0.33 (-0.25%)
HUMNL 6.74 Decreased By ▼ -0.11 (-1.61%)
KEL 4.35 Decreased By ▼ -0.04 (-0.91%)
KOSM 4.80 Increased By ▲ 0.46 (10.6%)
MLCF 37.19 Decreased By ▼ -0.56 (-1.48%)
OGDC 133.55 Decreased By ▼ -0.30 (-0.22%)
PAEL 22.60 Increased By ▲ 0.03 (0.13%)
PIAA 26.70 Decreased By ▼ -0.85 (-3.09%)
PIBTL 6.25 Decreased By ▼ -0.06 (-0.95%)
PPL 113.95 Decreased By ▼ -1.00 (-0.87%)
PRL 27.15 Decreased By ▼ -0.07 (-0.26%)
PTC 16.13 Decreased By ▼ -0.37 (-2.24%)
SEARL 59.70 Decreased By ▼ -1.00 (-1.65%)
SNGP 66.50 Increased By ▲ 1.35 (2.07%)
SSGC 11.21 Decreased By ▼ -0.14 (-1.23%)
TELE 8.94 Decreased By ▼ -0.03 (-0.33%)
TPLP 11.34 Increased By ▲ 0.09 (0.8%)
TRG 69.36 Increased By ▲ 0.31 (0.45%)
UNITY 23.45 Increased By ▲ 0.01 (0.04%)
WTL 1.36 Decreased By ▼ -0.03 (-2.16%)
BR100 7,312 Decreased By -12.8 (-0.17%)
BR30 24,105 Increased By 47 (0.2%)
KSE100 70,484 Decreased By -60.9 (-0.09%)
KSE30 23,203 Increased By 11.5 (0.05%)
World

Oxford-developed Malaria vaccine hailed as potential medical breakthrough

  • A malaria vaccine, developed by the University of Oxford, has proved to be 77% effective in early trials; being seen as a potential major breakthrough in the fight against the disease.
  • On the basis of these results, larger trials will now be carried out in nearly 5000 children between the ages of five months and three years, across four African states.
Published April 23, 2021

A malaria vaccine, developed by the University of Oxford, has proved to be 77% effective in early trials; being seen as a potential major breakthrough in the fight against the disease.

Malaria kills over 400,000 people every year, the majority of which are children in Sub-Saharan Africa.

Despite the fact that numerous vaccines have been trialled in the past, none has met the stipulated targets - making this recent development very significant.

The researchers from Oxford mentioned that the vaccine could have a major public health impact.

The vaccine, when trialled in a sample size of 450 children in Burkina Faso, was found to be safe, and showed "high-level efficacy" within over 12 months of follow-up.

On the basis of these results, larger trials will now be carried out in nearly 5000 children between the ages of five months and three years, across four African states.

Comments

Comments are closed.